Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury

IntroductionCisplatin-induced acute kidney injury (AKI) is primarily caused by oxidative stress from reactive oxygen species (ROS) accumulation. Developing ROS scavengers presents promising opportunities for preventing and treating this condition by targeting oxidative stress mechanisms.MethodsThis...

Full description

Saved in:
Bibliographic Details
Main Authors: Yunfeng Xiong, Huimin Kang, Yanping Rao, Xiayu Huang, Yang Zhu, Lixin Wei
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1535969/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850275341713539072
author Yunfeng Xiong
Huimin Kang
Yanping Rao
Xiayu Huang
Yang Zhu
Lixin Wei
Lixin Wei
author_facet Yunfeng Xiong
Huimin Kang
Yanping Rao
Xiayu Huang
Yang Zhu
Lixin Wei
Lixin Wei
author_sort Yunfeng Xiong
collection DOAJ
description IntroductionCisplatin-induced acute kidney injury (AKI) is primarily caused by oxidative stress from reactive oxygen species (ROS) accumulation. Developing ROS scavengers presents promising opportunities for preventing and treating this condition by targeting oxidative stress mechanisms.MethodsThis study involves the fabrication of a metal-polyphenol self-assembled nanozyme (Fe@Ba) designed to inhibit ferroptosis through synergistic catalytic actions and antioxidant properties. The nanozyme is constructed using metal-polyphenol coordination-driven nanoprecipitation techniques. Its performance is evaluated in vitro using MTEC cells and in vivo within an AKI model, with assessments of catalytic activities, ROS depletion efficacy, antioxidant effects, and anti-ferroptotic mechanisms.ResultsThe Fe@Ba nanozyme demonstrates significant catalase (CAT) and superoxide dismutase (SOD)-like activities upon internalization by MTEC cells, effectively reducing high ROS levels in the AKI model. Baicalein (Ba), a traditional Chinese medicine component in the nanozyme, exhibits strong antioxidant properties, inhibits lipid peroxidation (LPO), upregulates reductive glutathione (GSH), and promotes glutathione peroxidase 4 (GPX4) expression, thereby inhibiting ferroptosis. Fluorescence imaging confirms effective renal accumulation of Cy5.5-labeled Fe@Ba nanozyme. In vivo experiments show the nanozyme reduces inflammation and significantly enhances survival rates in AKI models.DiscussionThis study validates the concept of self-assembling nanozymes for AKI treatment and offers new insights into nanomedicine applications. The Fe@Ba nanozyme's ability to counteract inflammation-related damage and inhibit ferroptosis through multiple mechanisms highlights its therapeutic potential. The successful integration of traditional Chinese medicine components with nanotechnology represents an innovative approach to addressing cisplatin-induced AKI, suggesting broader applications for metal-polyphenol nanozymes in oxidative stress-related kidney diseases.
format Article
id doaj-art-aad1df3c52c54e74b6f9df1ca2d73d20
institution OA Journals
issn 1663-9812
language English
publishDate 2025-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj-art-aad1df3c52c54e74b6f9df1ca2d73d202025-08-20T01:50:45ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-04-011610.3389/fphar.2025.15359691535969Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injuryYunfeng Xiong0Huimin Kang1Yanping Rao2Xiayu Huang3Yang Zhu4Lixin Wei5Lixin Wei6Department of Nephrology, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Pediatrics, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Nephrology, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Nephrology, Fujian Medical University Union Hospital, Fuzhou, ChinaCAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry, University of Science and Technology of China, Hefei, ChinaDepartment of Nephrology, Fujian Medical University Union Hospital, Fuzhou, ChinaFujian Institute of Clinical Immunology, Fuzhou, ChinaIntroductionCisplatin-induced acute kidney injury (AKI) is primarily caused by oxidative stress from reactive oxygen species (ROS) accumulation. Developing ROS scavengers presents promising opportunities for preventing and treating this condition by targeting oxidative stress mechanisms.MethodsThis study involves the fabrication of a metal-polyphenol self-assembled nanozyme (Fe@Ba) designed to inhibit ferroptosis through synergistic catalytic actions and antioxidant properties. The nanozyme is constructed using metal-polyphenol coordination-driven nanoprecipitation techniques. Its performance is evaluated in vitro using MTEC cells and in vivo within an AKI model, with assessments of catalytic activities, ROS depletion efficacy, antioxidant effects, and anti-ferroptotic mechanisms.ResultsThe Fe@Ba nanozyme demonstrates significant catalase (CAT) and superoxide dismutase (SOD)-like activities upon internalization by MTEC cells, effectively reducing high ROS levels in the AKI model. Baicalein (Ba), a traditional Chinese medicine component in the nanozyme, exhibits strong antioxidant properties, inhibits lipid peroxidation (LPO), upregulates reductive glutathione (GSH), and promotes glutathione peroxidase 4 (GPX4) expression, thereby inhibiting ferroptosis. Fluorescence imaging confirms effective renal accumulation of Cy5.5-labeled Fe@Ba nanozyme. In vivo experiments show the nanozyme reduces inflammation and significantly enhances survival rates in AKI models.DiscussionThis study validates the concept of self-assembling nanozymes for AKI treatment and offers new insights into nanomedicine applications. The Fe@Ba nanozyme's ability to counteract inflammation-related damage and inhibit ferroptosis through multiple mechanisms highlights its therapeutic potential. The successful integration of traditional Chinese medicine components with nanotechnology represents an innovative approach to addressing cisplatin-induced AKI, suggesting broader applications for metal-polyphenol nanozymes in oxidative stress-related kidney diseases.https://www.frontiersin.org/articles/10.3389/fphar.2025.1535969/fullnanozymeacute kidney injuryferroptosiscisplatinreactive oxygen species
spellingShingle Yunfeng Xiong
Huimin Kang
Yanping Rao
Xiayu Huang
Yang Zhu
Lixin Wei
Lixin Wei
Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
Frontiers in Pharmacology
nanozyme
acute kidney injury
ferroptosis
cisplatin
reactive oxygen species
title Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
title_full Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
title_fullStr Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
title_full_unstemmed Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
title_short Metal-phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin-induced acute kidney injury
title_sort metal phenolic nanozyme as a ferroptosis inhibitor for alleviating cisplatin induced acute kidney injury
topic nanozyme
acute kidney injury
ferroptosis
cisplatin
reactive oxygen species
url https://www.frontiersin.org/articles/10.3389/fphar.2025.1535969/full
work_keys_str_mv AT yunfengxiong metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury
AT huiminkang metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury
AT yanpingrao metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury
AT xiayuhuang metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury
AT yangzhu metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury
AT lixinwei metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury
AT lixinwei metalphenolicnanozymeasaferroptosisinhibitorforalleviatingcisplatininducedacutekidneyinjury